首页> 外文期刊>Oncology letters >Lesion human leukocyte antigen-F expression is associated with a poor prognosis in patients with hepatocellular carcinoma
【24h】

Lesion human leukocyte antigen-F expression is associated with a poor prognosis in patients with hepatocellular carcinoma

机译:肝细胞癌患者病变中人类白细胞抗原F的表达与不良预后相关

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Human leukocyte antigen (HLA)-F, a non-classical HLA-class I molecule, has attracted attention as an important immunosuppressive molecule in recent years, although the clinical relevance of HLA-F expression in cancer patients remains unclear. In the present study, HLA-F expression in 90 primary hepatocellular carcinoma (HCC) lesions and 55 corresponding adjacent normal liver tissues was analyzed by immunohistochemistry, and the associations between HLA-F expression and clinicopathological parameters and patient survival times were analyzed. Positive HLA-F expression was observed in 47.8% (43/90) of the HCC lesions and in 10.9% (6/55) of the normal liver tissues. HLA-F expression in HCC lesions was significantly correlated with patient gender (P=0.02), and venous or lymphatic invasion (P=0.02). Patients who were HLA-F-positive had worse survival times than those who were HLA-F-negative (P=0.04). The mean overall survival times for HLA-F-negative and -positive patients were 44.2 months [95% confidence interval (CI), 37.7-50.7] and 33.0 months (95% CI, 25.1-40.8), respectively. Multivariate analysis revealed that HLA-F was an independent prognostic factor for HCC patients with a hazard ratio of 2.1 (95% CI, 1.0-4.4). In conclusion, the present study demonstrated that HLA-F expression was associated with poor survival in HCC patients, and is correlated with tumor cell invasion and metastasis.
机译:人类白细胞抗原(HLA)-F,一种非经典的HLA-I类分子,作为一种重要的免疫抑制分子,近年来受到关注,尽管在癌症患者中HLA-F表达的临床相关性尚不清楚。在本研究中,通过免疫组织化学分析了90例原发性肝细胞癌(HCC)病变和55个相应的相邻正常肝组织中HLA-F的表达,并分析了HLA-F的表达与临床病理参数和患者生存时间之间的关系。在HCC病变的47.8%(43/90)和正常肝组织的10.9%(6/55)中观察到HLA-F阳性表达。 HCC病变中HLA-F的表达与患者性别(P = 0.02),静脉或淋巴管浸润(P = 0.02)显着相关。 HLA-F阳性的患者比HLA-F阴性的患者的生存时间更差(P = 0.04)。 HLA-F阴性和阳性患者的平均总生存时间分别为44.2个月[95%置信区间(CI),37.7-50.7]和33.0个月(95%CI,25.1-40.8)。多变量分析显示,HLA-F是HCC患者的独立预后因素,危险比为2.1(95%CI,1.0-4.4)。总之,本研究表明HLA-F表达与肝癌患者的不良生存有关,并且与肿瘤细胞的侵袭和转移有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号